Epidarex Capital

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Funderbeam Ou operates investing and trading platform for investors to buy and sell equity stakes in private companies. It operates a funding and trading platform for high-growth private companies. The company’s platform helps founders raise funds and provides access liquidity to early stage equity investors. The company was founded in 2013 and is based in Tallinn, Estonia with an additional office in London, United Kingdom.

Eternygen GmbH, a biotechnology company, engages in the research, development, and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The company was incorporated in 2012 and is based in Berlin, Germany with an additional office in the United Kingdom.

Lunac Therapeutics is a UK-based drug discovery company.

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.

Epsilogen Ltd, an immuno-oncology company, develops and offers immunoglobulin E (IgE) antibodies to treat cancer. The company offers a portfolio of IgE candidates that target cancer antigens such as HER2, EGFR, and PD-L1. It also develops an IgE platform that supports the development of the IP and manufacturing validation of novel antibodies. The company was founded in 2016 and is based in London, United Kingdom.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.

Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Clyde Biosciences Ltd. offers developmental drug testing solutions that provide clients with insights into the working mechanisms and actions of drugs in research and development, as well as enable them to evaluate the drug toxicity. It develops cellOPTIQ, an optical action potential assay providing clients with an understanding of the effects of drug compounds on human cells to address unmet needs in testing cardiotoxicity risk in new and existing drugs. The company also develops XTENDSR, a solution that provides clients with direct measurements of drug induced changes on cardiac sarcoplasmic reticulum function. It serves pharmaceutical and biotechnology companies in the United Kingdom and internationally. Clyde Biosciences Ltd. was founded in 2012 and is based in Glasgow, United Kingdom.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Confluence Life Sciences, Inc. operates as a KINect technology based company that focuses on drug design to identify mechanistically novel drugs. It develops a portfolio of projects to address unmet medical needs in caner and chronic inflammatory diseases. The company focuses on designing and developing kinase inhibitors that target key enzymes involved in the regulation of cancer growth, survival and metastasis, or in the modulation of chronic inflammation. Its KINect technology platform enables the identification and development of new protein kinase drugs. Confluence Life Sciences, Inc. was founded in 2010 and is based in Saint Louis, Missouri. As of August 3, 2017, Confluence Life Sciences, Inc. operates as a subsidiary of Aclaris Life Sciences, Inc.

Caldan Therapeutics Ltd. develops and markets therapeutics targeting free fatty acid receptors for Type 2 Diabetes (T2D) and other potential indications. The company focuses on developing drugs that activate these receptors in order to deliver anti-diabetic effects in multiple tissues and organs. The company was incorporated in 2015 and is based in Glasgow, United Kingdom.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.

Eternygen GmbH, a biotechnology company, engages in the research, development, and marketing of NaCT inhibitors for the treatment of dietary-related metabolic diseases. The company was incorporated in 2012 and is based in Berlin, Germany with an additional office in the United Kingdom.

LUNAC Therapeutics Limited engages in identification and development of advanced anticoagulants. The company was incorporated in 2018 and is based in Leeds, United Kingdom.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

Epsilogen Ltd, an immuno-oncology company, develops and offers immunoglobulin E (IgE) antibodies to treat cancer. The company offers a portfolio of IgE candidates that target cancer antigens such as HER2, EGFR, and PD-L1. It also develops an IgE platform that supports the development of the IP and manufacturing validation of novel antibodies. The company was founded in 2016 and is based in London, United Kingdom.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications. The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU). Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

Epsilogen Ltd, an immuno-oncology company, develops and offers immunoglobulin E (IgE) antibodies to treat cancer. The company offers a portfolio of IgE candidates that target cancer antigens such as HER2, EGFR, and PD-L1. It also develops an IgE platform that supports the development of the IP and manufacturing validation of novel antibodies. The company was founded in 2016 and is based in London, United Kingdom.

Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Transine Therapeutics

Edinburgh Molecular Imaging Limited operates as a biotechnology company focusing on enabling image-guided therapy to detect, diagnose, and monitor diseases. It offers molecular imaging technology based on fluorescent imaging to detect disease in real-time during interventional procedures, including surgery and accurate treatment. The company discovers and develops small molecules and peptides that conjugate with fluorescent dyes, cancerous cells, and other diseased tissue. Its optical imaging platform detects disease in real-time during interventional procedures. Edinburgh Molecular Imaging Limited was founded in 2014 and is based in Edinburgh, United Kingdom.

Funderbeam Ou operates investing and trading platform for investors to buy and sell equity stakes in private companies. It operates a funding and trading platform for high-growth private companies. The company’s platform helps founders raise funds and provides access liquidity to early stage equity investors. The company was founded in 2013 and is based in Tallinn, Estonia with an additional office in London, United Kingdom.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.

NodThera Limited researches and develops novel inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. It develops Inflammasomes, which are multi-protein complexes to treat a range of diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company was incorporated in 2016 and is based in Little Chesterford, United Kingdom with a laboratory in Seattle, Washington; and a corporate office in Lexington, Massachusetts.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.

SIRAKOSS Ltd., a medical device company, develops synthetic bone graft substitutes for the treatment of bone defects and fusions. Its products include MaxSi graft granules; and MaxSi graft granules in a putty system that are shaped by the surgeon and administered directly at the defect site. The company was founded in 2010 and is based in Edinburgh, United Kingdom. As of November 5, 2020, SIRAKOSS Ltd. operates as a subsidiary of OssDsign AB (publ).

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

Macomics Ltd develops immunotherapies that helps to modulate macrophages and increase body’s immune system against tumours. The company was incorporated in 2018 and is based in Edinburgh, United Kingdom.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors. Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Tailor Bio Ltd develops an oncology diagnostics platform. Its platform identifies patterns in tumor deoxyribonucleic acid (DNA) to predict a patient’s response to cancer drugs. Tailor Bio Ltd was formerly known as PINPOINT ONCOLOGY LTD and changed its name to Tailor Bio Ltd in April 2020. The company was incorporated in 2019 and is based in London, United Kingdom.

Clyde Biosciences Ltd. offers developmental drug testing solutions that provide clients with insights into the working mechanisms and actions of drugs in research and development, as well as enable them to evaluate the drug toxicity. It develops cellOPTIQ, an optical action potential assay providing clients with an understanding of the effects of drug compounds on human cells to address unmet needs in testing cardiotoxicity risk in new and existing drugs. The company also develops XTENDSR, a solution that provides clients with direct measurements of drug induced changes on cardiac sarcoplasmic reticulum function. It serves pharmaceutical and biotechnology companies in the United Kingdom and internationally. Clyde Biosciences Ltd. was founded in 2012 and is based in Glasgow, United Kingdom.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

Edinburgh Molecular Imaging Limited operates as a biotechnology company focusing on enabling image-guided therapy to detect, diagnose, and monitor diseases. It offers molecular imaging technology based on fluorescent imaging to detect disease in real-time during interventional procedures, including surgery and accurate treatment. The company discovers and develops small molecules and peptides that conjugate with fluorescent dyes, cancerous cells, and other diseased tissue. Its optical imaging platform detects disease in real-time during interventional procedures. Edinburgh Molecular Imaging Limited was founded in 2014 and is based in Edinburgh, United Kingdom.

Slate Bio is an immunotherapeutics development company that develops therapies that restore the body's natural immunological response in different diseases using bifunctional IL233 cytokine, thereby providing users with an independent synergistic pathway that has greater tissue selectivity and improved pharmacodynamics.

Topas Therapeutics GmbH operates as a biotechnology company that is engaged in developing nanoparticle-based therapeutics. The company builds neuro based pipeline of clinical-stage development therapeutics and projects to treat autoimmune diseases such as multiple sclerosis. The company develops nanoparticle technology to target autoimmune, allergies, anti-drug antibodies, and inflammatory diseases through the induction of antigen specific immune tolerance in the liver. The company’s platform promotes immune tolerance to blood antigens. Topas Therapeutics GmbH was incorporated in 2013 and is based in Hamburg, Germany.

Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

Lunac Therapeutics is a UK-based drug discovery company.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Edinburgh Molecular Imaging Limited operates as a biotechnology company focusing on enabling image-guided therapy to detect, diagnose, and monitor diseases. It offers molecular imaging technology based on fluorescent imaging to detect disease in real-time during interventional procedures, including surgery and accurate treatment. The company discovers and develops small molecules and peptides that conjugate with fluorescent dyes, cancerous cells, and other diseased tissue. Its optical imaging platform detects disease in real-time during interventional procedures. Edinburgh Molecular Imaging Limited was founded in 2014 and is based in Edinburgh, United Kingdom.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.